This is based on the fact that tumor cells can release pro-coagulant factors, especially tissue factor (TF) [5], which is now recognized as the major initiator of the clotting cascade in vitro. TF is a transmembrane glycoprotein, also known as thromboplastin, which is overexpressed on cancer cells [6]. The gene discussed is F3; the disease is neoplasm.